Cargando…
18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation
PURPOSE: Focal congenital hyperinsulinism (CHI) is curable by surgery, which is why identification of the focal lesion is crucial. We aimed to determine the use of 18F–fluoro-dihydroxyphenylalanine (18F-DOPA) PET/CT vs. 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic-acid-1-Nal3-octreotide...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745571/ https://www.ncbi.nlm.nih.gov/pubmed/29116340 http://dx.doi.org/10.1007/s00259-017-3867-1 |
_version_ | 1783288928238829568 |
---|---|
author | Christiansen, Charlotte Dahl Petersen, Henrik Nielsen, Anne Lerberg Detlefsen, Sönke Brusgaard, Klaus Rasmussen, Lars Melikyan, Maria Ekström, Klas Globa, Evgenia Rasmussen, Annett Helleskov Hovendal, Claus Christesen, Henrik Thybo |
author_facet | Christiansen, Charlotte Dahl Petersen, Henrik Nielsen, Anne Lerberg Detlefsen, Sönke Brusgaard, Klaus Rasmussen, Lars Melikyan, Maria Ekström, Klas Globa, Evgenia Rasmussen, Annett Helleskov Hovendal, Claus Christesen, Henrik Thybo |
author_sort | Christiansen, Charlotte Dahl |
collection | PubMed |
description | PURPOSE: Focal congenital hyperinsulinism (CHI) is curable by surgery, which is why identification of the focal lesion is crucial. We aimed to determine the use of 18F–fluoro-dihydroxyphenylalanine (18F-DOPA) PET/CT vs. 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic-acid-1-Nal3-octreotide (68Ga-DOTANOC) PET/CT as diagnostic tools in focal CHI. METHODS: PET/CT scans of children with CHI admitted to Odense University Hospital between August 2005 and June 2016 were retrospectively evaluated visually and by their maximal standardized uptake values (SUV(max)) by two independent examiners, blinded for clinical, surgical and pathological data. Pancreatic histology was used as the gold standard. For patients without surgery, the genetic profile served as the gold standard. RESULTS: Fifty-five CHI patients were examined by PET/CT (18F-DOPA n = 53, 68Ga-DOTANOC n = 18). Surgery was performed in 34 patients, no surgery in 21 patients. Fifty-one patients had a classifiable outcome, either by histology (n = 33, 22 focal lesions, 11 non-focal) or by genetics (n = 18, all non-focal). The predictive performance of 18F-DOPA PET/CT to identify focal CHI was identical by visual- and cut-off-based evaluation: sensitivity (95% CI) of 1 (0.85–1); specificity of 0.96 (0.82–0.99). The optimal 18F-DOPA PET SUV(max) ratio cut-off was 1.44 and the optimal 68Ga-DOTANOC PET SUV(max) cut-off was 6.77 g/ml. The area under the receiver operating curve was 0.98 (0.93–1) for 18F-DOPA PET vs. 0.71 (0.43–0.95) for 68Ga-DOTANOC PET (p < 0.03). In patients subjected to surgery, localization of the focal lesion was correct in 91%, and 100%, by 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT, respectively. CONCLUSION: 18F-DOPA PET/CT was excellent in predicting focal CHI and superior compared to 68Ga-DOTANOC PET/CT. Further use of 68GA-DOTANOC PET/CT in predicting focal CHI is discouraged. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-017-3867-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5745571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-57455712018-01-08 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation Christiansen, Charlotte Dahl Petersen, Henrik Nielsen, Anne Lerberg Detlefsen, Sönke Brusgaard, Klaus Rasmussen, Lars Melikyan, Maria Ekström, Klas Globa, Evgenia Rasmussen, Annett Helleskov Hovendal, Claus Christesen, Henrik Thybo Eur J Nucl Med Mol Imaging Original Article PURPOSE: Focal congenital hyperinsulinism (CHI) is curable by surgery, which is why identification of the focal lesion is crucial. We aimed to determine the use of 18F–fluoro-dihydroxyphenylalanine (18F-DOPA) PET/CT vs. 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic-acid-1-Nal3-octreotide (68Ga-DOTANOC) PET/CT as diagnostic tools in focal CHI. METHODS: PET/CT scans of children with CHI admitted to Odense University Hospital between August 2005 and June 2016 were retrospectively evaluated visually and by their maximal standardized uptake values (SUV(max)) by two independent examiners, blinded for clinical, surgical and pathological data. Pancreatic histology was used as the gold standard. For patients without surgery, the genetic profile served as the gold standard. RESULTS: Fifty-five CHI patients were examined by PET/CT (18F-DOPA n = 53, 68Ga-DOTANOC n = 18). Surgery was performed in 34 patients, no surgery in 21 patients. Fifty-one patients had a classifiable outcome, either by histology (n = 33, 22 focal lesions, 11 non-focal) or by genetics (n = 18, all non-focal). The predictive performance of 18F-DOPA PET/CT to identify focal CHI was identical by visual- and cut-off-based evaluation: sensitivity (95% CI) of 1 (0.85–1); specificity of 0.96 (0.82–0.99). The optimal 18F-DOPA PET SUV(max) ratio cut-off was 1.44 and the optimal 68Ga-DOTANOC PET SUV(max) cut-off was 6.77 g/ml. The area under the receiver operating curve was 0.98 (0.93–1) for 18F-DOPA PET vs. 0.71 (0.43–0.95) for 68Ga-DOTANOC PET (p < 0.03). In patients subjected to surgery, localization of the focal lesion was correct in 91%, and 100%, by 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT, respectively. CONCLUSION: 18F-DOPA PET/CT was excellent in predicting focal CHI and superior compared to 68Ga-DOTANOC PET/CT. Further use of 68GA-DOTANOC PET/CT in predicting focal CHI is discouraged. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-017-3867-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-11-08 2018 /pmc/articles/PMC5745571/ /pubmed/29116340 http://dx.doi.org/10.1007/s00259-017-3867-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Christiansen, Charlotte Dahl Petersen, Henrik Nielsen, Anne Lerberg Detlefsen, Sönke Brusgaard, Klaus Rasmussen, Lars Melikyan, Maria Ekström, Klas Globa, Evgenia Rasmussen, Annett Helleskov Hovendal, Claus Christesen, Henrik Thybo 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation |
title | 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation |
title_full | 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation |
title_fullStr | 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation |
title_full_unstemmed | 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation |
title_short | 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation |
title_sort | 18f-dopa pet/ct and 68ga-dotanoc pet/ct scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745571/ https://www.ncbi.nlm.nih.gov/pubmed/29116340 http://dx.doi.org/10.1007/s00259-017-3867-1 |
work_keys_str_mv | AT christiansencharlottedahl 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT petersenhenrik 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT nielsenannelerberg 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT detlefsensonke 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT brusgaardklaus 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT rasmussenlars 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT melikyanmaria 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT ekstromklas 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT globaevgenia 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT rasmussenannetthelleskov 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT hovendalclaus 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation AT christesenhenrikthybo 18fdopapetctand68gadotanocpetctscansasdiagnostictoolsinfocalcongenitalhyperinsulinismablindedevaluation |